Cannabidiol
CAS 13956-29-1
Cannabidiol (CAS 13956-29-1) is a Phase 4 pharmaceutical compound with 26 bioactivity targets and 1,179 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 23142.338888888888 nM | 72 | - |
| - | IC50 | 19303.661698113207 nM | 52 | - |
| - | EC50 | 4473.168952380952 nM | 42 | - |
| - | Ki | 5826.289473684211 nM | 38 | - |
| - | MIC | 21.521941176470587 ug.mL-1 | 17 | - |
| - | EC50 | 114.66666666666667 mg kg-1 | 3 | - |
| - | Kd | 0.078 1/s | 1 | - |
| - | Kd | 18.8 nM | 1 | - |
| Cannabinoid receptor 1 GPCR |
Ki | 5.62 | - | Homo sapiens |
| Mu-type opioid receptor GPCR |
Ki | 5.89 | - | Homo sapiens |
| D(1A) dopamine receptor GPCR |
Ki | 5.57 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 1A GPCR |
EC50 | 5.1 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 2C GPCR |
Ki | 5.96 | - | Homo sapiens |
| Alpha-2B adrenergic receptor GPCR |
Ki | 5.5 | - | Homo sapiens |
| Alpha-2C adrenergic receptor GPCR |
Ki | 5.43 | - | Homo sapiens |
| Kappa-type opioid receptor GPCR |
Ki | 5.64 | - | Homo sapiens |
| Delta-type opioid receptor GPCR |
Ki | 5.19 | - | Homo sapiens |
| Caspase-1 Enzyme |
Kd | 7.73 | - | Homo sapiens |
| Cannabinoid receptor 2 GPCR |
Ki | 5.54 | - | Homo sapiens |
| Histamine H3 receptor GPCR |
Ki | 5.51 | - | Homo sapiens |
| N-arachidonyl glycine receptor GPCR |
EC50 | 4.29 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 2A GPCR |
EC50 | 4.5 | - | Rattus norvegicus |
| Acetylcholinesterase Enzyme |
IC50 | 4.77 | - | Electrophorus electricus |
| Cannabinoid receptor 1 GPCR |
Ki | 5.9 | - | Rattus norvegicus |
| Cannabinoid receptor 2 GPCR |
Ki | 6.64 | - | Mus musculus |
| Fatty-acid amide hydrolase 1 Enzyme |
IC50 | 4.27 | - | Rattus norvegicus |
| Cholinesterase Enzyme |
IC50 | 6.17 | - | Equus caballus |
| L-lactate dehydrogenase A chain Enzyme |
Ki | 4.62 | - | Homo sapiens |
| Transient receptor potential cation channel subfamily M member 8 Ion channel |
IC50 | 5.55 | - | Rattus norvegicus |
| Transient receptor potential cation channel subfamily V member 2 Ion channel |
EC50 | 5.43 | - | Rattus norvegicus |
| Transient receptor potential cation channel subfamily A member 1 Ion channel |
IC50 | 6.35 | - | Rattus norvegicus |
| Transmembrane protein 97 Enzyme |
Ki | 5.47 | - | Homo sapiens |
| Transient receptor potential cation channel subfamily V member 2 Ion channel |
EC50 | 4.5 | - | Homo sapiens |
| Heat sensitive channel TRPV3 Unclassified |
EC50 | 6.29 | - | Rattus norvegicus |
| Transient receptor potential cation channel subfamily V member 4, TrpV4 Unclassified |
EC50 | 6.05 | - | Rattus norvegicus |
| Transient receptor potential cation channel subfamily V member 1 Ion channel |
IC50 | 5.43 | - | Homo sapiens |
| G-protein coupled receptor 55 GPCR |
EC50 | 6.35 | - | Homo sapiens |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Seizure | 2304 | 6270.621 | 10039906 |
| Product use in unapproved indication | 912 | 1389.09 | 10076476 |
| Somnolence | 606 | 750.704 | 10041349 |
| Product dose omission issue | 579 | 613.409 | 10084406 |
| Diarrhoea | 852 | 393.241 | 10012735 |
| Aggression | 198 | 323.727 | 10001488 |
| Seizure cluster | 59 | 291.075 | 10071350 |
| Product supply issue | 64 | 224.552 | 10077801 |
| Generalised tonic-clonic seizure | 137 | 205.944 | 10018100 |
| Product administration interrupted | 70 | 191.593 | 10081479 |
| Product distribution issue | 55 | 190.584 | 10071148 |
| Change in seizure presentation | 41 | 181.623 | 10075606 |
| Multiple-drug resistance | 72 | 167.522 | 10048723 |
| Lethargy | 152 | 152.836 | 10024264 |
| Anticonvulsant drug level increased | 47 | 144.091 | 10057856 |
| Atonic seizures | 36 | 142.584 | 10003628 |
| Sedation | 120 | 140.999 | 10039897 |
| Weight abnormal | 42 | 136.343 | 10056814 |
| Hypersomnia | 87 | 133.885 | 10020765 |
| Drug interaction | 323 | 127.185 | 10013710 |
| Irritability | 108 | 126.976 | 10022998 |
| Abnormal behaviour | 98 | 123.912 | 10061422 |
| Status epilepticus | 80 | 122.862 | 10041962 |
| Weight increased | 278 | 120.157 | 10047899 |
| Behaviour disorder | 52 | 116.546 | 10004207 |
| Product administered to patient of inappropriate age | 51 | 115.764 | 10081578 |
| Incorrect route of product administration | 92 | 110.17 | 10081202 |
| Acute kidney injury | 10 | 106.786 | 10069339 |
| Decreased appetite | 285 | 106.606 | 10061428 |
| Drooling | 47 | 106.329 | 10013642 |
| Psychomotor hyperactivity | 60 | 93.061 | 10037211 |
| Agitation | 128 | 91.093 | 10001497 |
| Prescribed overdose | 84 | 91.083 | 10051076 |
| Insurance issue | 43 | 90.253 | 10078156 |
| Anger | 62 | 88.269 | 10002368 |
| Drug ineffective | 661 | 82.34 | 10013709 |
| Tonic convulsion | 29 | 81.769 | 10043994 |
| Off label use | 550 | 80.867 | 10053762 |
| Device related thrombosis | 30 | 80.826 | 10077455 |
| Sudden unexplained death in epilepsy | 22 | 78.465 | 10063894 |
| Petit mal epilepsy | 34 | 68.445 | 10034759 |
| Weight decreased | 259 | 67.146 | 10047895 |
| Hospitalisation | 124 | 66.977 | 10054112 |
| Dyspnoea | 96 | 66.752 | 10013968 |
| Insomnia | 199 | 61.937 | 10022437 |
| Emergency care | 21 | 60.522 | 10066400 |
| Blood pressure diastolic decreased | 60 | 57.443 | 10005737 |
| Oedema peripheral | 5 | 56.63 | 10030124 |
| Product prescribing issue | 27 | 54.037 | 10080459 |
| Product container issue | 22 | 52.928 | 10069293 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| CB 1 receptor CNR1 |
Negative | - | 26218440 |
| GPR18 GPR18 |
Partial agonist | 4.29 pEC50 | 21595653 |
| GPR55 GPR55 |
Antagonist | 6.35 pIC50 | 17876302|21079038 |
| Na v 1.1 SCN1A |
Channel blocker | 5.539999961853027 pIC50 | 30219789 |
| Na v 1.1 SCN1A |
Channel blocker | 4.900000095367432 pIC50 | 30219789 |
| Na v 1.2 SCN2A |
Channel blocker | 5.539999961853027 pIC50 | 30219789 |
| Na v 1.3 SCN3A |
Channel blocker | 5.480000019073486 pIC50 | 30219789 |
| Na v 1.4 SCN4A |
Channel blocker | 5.71999979019165 pIC50 | 30219789 |
| Na v 1.4 SCN4A |
Channel blocker | 5.0 pIC50 | 33836525 |
| Na v 1.5 SCN5A |
Channel blocker | 5.420000076293945 pIC50 | 30219789 |
| Na v 1.6 SCN8A |
Channel blocker | 5.519999980926514 pIC50 | 30219789 |
| Na v 1.7 SCN9A |
Channel blocker | 5.539999961853027 pIC50 | 30219789|37330538 |
| Na v 1.8 Scn10a |
Channel blocker | 5.699999809265137 pIC50 | 39835903 |
| TRPA1 Trpa1 |
Agonist | 6.320000171661377 pEC50 | 32880179 |
| TRPM8 Trpm8 |
Antagonist | 5.550000190734863 pIC50 | 32880179 |
| TRPV2 Trpv2 |
Activation | 5.43 pEC50 | 18550765 |
| TRPV2 TRPV2 |
Activation | 4.5 pEC50 | 18550765 |
| TRPV3 Trpv3 |
Activation | 5.43 pEC50 | 21726418 |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| CANNABIDIOL | 2045371 | SU | MTHSPL |
| cannabidiol | 2045371 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Cannabidiol used for in pharmaceutical contexts?
Cannabidiol (CAS 13956-29-1) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Cannabidiol?
Cannabidiol has 1,179 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Seizure, Product use in unapproved indication, Somnolence, Product dose omission issue, Diarrhoea. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Cannabidiol also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Cannabidiol (CBD) with EU status "permitted".
What clinical phase is Cannabidiol in?
Cannabidiol is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Cannabidiol?
Cannabidiol has 37 bioactivity rows in this page query. Rendered target entries include Cannabinoid receptor 1, Mu-type opioid receptor, D(1A) dopamine receptor, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2C.